Evidence map›Paper›PMID 34727959›Full record

SynthesisOrphanet journal of rare diseases2021

A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease.

Ahmar U Zaidi, Alexander K Glaros, Soyon Lee, Taiji Wang, Rhea Bhojwani, Eric Morris, Breanne Donohue, Jincy Paulose, Şerban R Iorga, Dave Nellesen

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Updated Review of Current Therapeutic Approaches for the Management of Sickle Cell Disease.Cardiovascular & hematological disorders drug targets · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Observational
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Ahmar U ZaidiChildren's Hospital of Michigan, Detroit, MI, USA.
Alexander K GlarosChildren's Hospital of Michigan, Detroit, MI, USA.
Soyon LeeNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Taiji WangAnalysis Group, Inc., 1010 El Camino Real, Suite 310, Menlo Park, CA, 94025, USA. Taiji.Wang@analysisgroup.com.ORCID 0000-0001-7236-5998
Rhea BhojwaniAnalysis Group, Inc., 1010 El Camino Real, Suite 310, Menlo Park, CA, 94025, USA.
Eric MorrisAnalysis Group, Inc., 1010 El Camino Real, Suite 310, Menlo Park, CA, 94025, USA.
Breanne DonohueNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Jincy PauloseNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Şerban R IorgaNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Dave NellesenAnalysis Group, Inc., 1010 El Camino Real, Suite 310, Menlo Park, CA, 94025, USA.
Analysis Group (United States) · USNovartis (United States) · USCentral Michigan University · USChildren's Hospital of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeSickle cell disease (SCD) is a collection of rare inherited blood disorders affecting approximately 100,000 people in the U.S. and 20-25 million people globally. Individuals with SCD experience recurrent episodes of severe and unpredictable pain that are caused by vaso-occlusive crises (VOCs), a hallmark of the disease. VOCs are the primary cause of hospitalization in SCD, result in missed workdays and school days, and decrease quality of life (QoL). Although VOCs cause significant burden in the lives of individuals with SCD, there is no synthesis on the frequency of VOCs in the real world. This systematic literature review sought to identify literature describing the frequency of VOCs experienced by individuals with SCD in real-world settings.

methodsMEDLINE and 6 congresses were searched (date range: January 1, 2000 to June 30, 2020). Studies were reviewed independently by two researchers. Studies assessing frequency or prevalence of VOCs or VOC-related outcomes were included.

resultsOf 1438 studies identified in the search, 52 met pre-specified inclusion and exclusion criteria. Reported frequency of VOCs varied widely ranging from a mean or median of 0 VOCs/year to 18.2 VOCs/year. The proportion of patients experiencing ≥ 3 VOCs/year ranged from 4 to 67% and the proportion of patients experiencing ≥ 5 VOCs/year ranged from 18 to 59%. Measures of VOC severity were limited, with 13 studies considering frequency of complicated VOCs and only 1 study reporting duration of VOC episodes.

conclusionsThis is the first study to systematically assess published evidence pertaining to VOCs in real-world settings. Reported VOC frequency in real-world settings varied widely, with a majority of studies only considering VOCs managed in an inpatient or outpatient setting. Studies that considered VOCs managed at home reported a higher frequency of VOCs, suggesting that many studies may underestimate the frequency of VOCs. This systematic literature review (SLR) highlights the need for consistent reporting of (1) self-reported VOCs, including those managed at home, (2) definitions of VOCs, (3) complicated VOCs, and (4) duration of VOC episodes in literature.

Indexed as

Anemia, Sickle CellQuality of LifeHospitalizationHumansPainIncidencePain crisisPrevalenceReal-worldSickle cell diseaseVaso-occlusive crisis

Identifiers

PMID34727959
PMCPMC8561926
OpenAlexW3210066898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.